Racigen Therapeutics, a global innovative small nucleic acid drug development startup, announced the completion of nearly 200 million yuan of A+ round financing. This round of financing will be mainly used to promote several preclinical projects to the clinical stage, expand nucleic acid production capacity and accelerate the process of internationalization.

As a novel gene-targeting platform technology, saRNA drugs activate gene expression via a mechanism known as RNA activation (RNAa) boosting protein levels in diseases caused by insufficient protein expression. RNAa is a biological mechanism first discovered and named in 2006 by Dr. Long-Cheng Li, co-founder of Ractigen Therapeutics.

Since its establishment in 2017, Racigen Therapeutics has actively promoted more than ten saRNA drug R&D pipelines in just over four years. Pipeline indications cover genetic diseases, tumors, liver targets, central nervous system, ophthalmic diseases and other fields. At present, four pipelines are in preclinical development stage. At the same time, the company has built two key technology platforms of "Smart-TTC" and "SCAD" with independent intellectual property rights.